Theralase prices up to C$4 million private placement at C$0.24 per unit

20+ Year Trsy Bond Ishares

TLT

0.00

Theralase launched brokered private placement under Listed Issuer Financing Exemption, targeting gross proceeds of C$ 3 million to C$ 4 million at C$ 0.24 per unit.
Each unit includes 1 common share plus 1 warrant exercisable at C$ 0.32 for 60 months; company plans to seek TSXV listing for warrants.
Agent option allows upsize of offering by up to 15%.
Proceeds earmarked for Phase II non-muscle invasive bladder cancer study, GLP toxicology work for intravenous Rutherrin, working capital; maximum raise adds GLP tox for topical Ruvidar for cold sores.
Closing targeted for May 20, 2026, subject to required approvals including TSXV.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.